Neumora Therapeutics (NMRA) Cash & Equivalents (2022 - 2026)

Neumora Therapeutics' Cash & Equivalents history runs 5 years deep, the most recent figure standing at $147.1 million for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 15.93% year-over-year to $147.1 million; the TTM figure through Mar 2026 stood at $147.1 million (up 15.93% YoY), while the FY2025 annual figure was $182.5 million, up 28.41% from the prior year.
• Cash & Equivalents was $147.1 million for Q1 2026 at Neumora Therapeutics, down from $182.5 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $412.3 million in Q3 2023 to a low of $124.5 million in Q2 2025.
• Historically, Cash & Equivalents has averaged $210.4 million across 5 years, with a median of $182.9 million in 2024.
• The sharpest annual moves came in 2023 and 2024: Cash & Equivalents surged 63.27% in 2023, then tumbled 62.0% in 2024.
• A 5-year view of Cash & Equivalents shows it stood at $240.9 million in 2022, then surged by 55.24% to $374.0 million in 2023, then sank by 62.0% to $142.1 million in 2024, then climbed by 28.41% to $182.5 million in 2025, then decreased by 19.43% to $147.1 million in 2026.
• The last three Cash & Equivalents figures came in at $147.1 million (Q1 2026), $182.5 million (Q4 2025), and $129.1 million (Q3 2025), per Business Quant data.